Ann R Falsey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5813669/publications.pdf Version: 2024-02-01

117 papers	12,111 citations	41344 49 h-index	²⁹¹⁵⁷ 104 g-index
paporo			5 maon
127 all docs	127 docs citations	127 times ranked	13710 citing authors

#	Article	IF	CITATIONS
1	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 2020, 383, 2439-2450.	27.0	2,107
2	Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults. New England Journal of Medicine, 2005, 352, 1749-1759.	27.0	1,668
3	Human Metapneumovirus Infections in Young and Elderly Adults. Journal of Infectious Diseases, 2003, 187, 785-790.	4.0	504
4	Respiratory Syncytial Virus and Influenza A Infections in the Hospitalized Elderly. Journal of Infectious Diseases, 1995, 172, 389-394.	4.0	358
5	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases, The, 2018, 18, e295-e311.	9.1	355
6	Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 95-107.	9.1	337
7	Randomized, Doubleâ€Blind Controlled Phase 3 Trial Comparing the Immunogenicity of Highâ€Dose and Standardâ€Dose Influenza Vaccine in Adults 65 Years of Age and Older. Journal of Infectious Diseases, 2009, 200, 172-180.	4.0	334
8	Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. The Cochrane Library, 2019, 2019, CD007498.	2.8	320
9	Global Disease Burden Estimates of Respiratory Syncytial Virus–Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2020, 222, S577-S583.	4.0	231
10	Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness. Journal of Infectious Diseases, 2014, 209, 1873-1881.	4.0	206
11	Viral Pneumonia in Older Adults. Clinical Infectious Diseases, 2006, 42, 518-524.	5.8	189
12	Rhinovirus and Coronavirus Infection–Associated Hospitalizations among Older Adults. Journal of Infectious Diseases, 2002, 185, 1338-1341.	4.0	184
13	Risk Factors for Severe Respiratory Syncytial Virus Infection in Elderly Persons. Journal of Infectious Diseases, 2004, 189, 233-238.	4.0	183
14	Humoral and Mucosal Immunity in Protection from Natural Respiratory Syncytial Virus Infection in Adults. Journal of Infectious Diseases, 2004, 190, 373-378.	4.0	163
15	Respiratory Syncytial Virus Infection in Elderly Adults. Drugs and Aging, 2005, 22, 577-587.	2.7	159
16	Diagnosis of Respiratory Syncytial Virus Infection: Comparison of Reverse Transcription-PCR to Viral Culture and Serology in Adults with Respiratory Illness. Journal of Clinical Microbiology, 2002, 40, 817-820.	3.9	153
17	Superiority of Transcriptional Profiling Over Procalcitonin for Distinguishing Bacterial From Viral Lower Respiratory Tract Infections in Hospitalized Adults. Journal of Infectious Diseases, 2015, 212, 213-222.	4.0	146
18	Clinical Impact of Human Coronaviruses 229E and OC43 Infection in Diverse Adult Populations. Journal of Infectious Diseases, 2013, 208, 1634-1642.	4.0	145

#	Article	IF	CITATIONS
19	Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. Journal of Clinical Virology, 2003, 28, 169-174.	3.1	141
20	Parainfluenza Virus Infection. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 538-554.	2.1	140
21	Respiratory Syncytial Virus Infection in Adults. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 171-181.	2.1	138
22	Bacterial Complications of Respiratory Tract Viral Illness: A Comprehensive Evaluation. Journal of Infectious Diseases, 2013, 208, 432-441.	4.0	127
23	Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem. Drugs and Aging, 2015, 32, 261-269.	2.7	123
24	Detection of Respiratory Syncytial Virus in Adults with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 639-643.	5.6	121
25	Comparison of Quantitative Reverse Transcription-PCR to Viral Culture for Assessment of Respiratory Syncytial Virus Shedding. Journal of Clinical Microbiology, 2003, 41, 4160-4165.	3.9	112
26	The Diagnosis of Viral Respiratory Disease in Older Adults. Clinical Infectious Diseases, 2010, 50, 100201102709029-000.	5.8	111
27	Viral Shedding and Immune Responses to Respiratory Syncytial Virus Infection in Older Adults. Journal of Infectious Diseases, 2013, 207, 1424-1432.	4.0	110
28	Acute Respiratory Tract Infection in Daycare Centers for Older Persons. Journal of the American Geriatrics Society, 1995, 43, 30-36.	2.6	107
29	Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial. Journal of Infectious Diseases, 2015, 212, 1692-1700.	4.0	103
30	Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illness. Journal of Clinical Virology, 2006, 35, 46-50.	3.1	102
31	Respiratory Syncytial Virus Infection in Adult Populations. Infectious Disorders - Drug Targets, 2012, 12, 98-102.	0.8	101
32	Serum antibody decay in adults following natural respiratory syncytial virus infection. Journal of Medical Virology, 2006, 78, 1493-1497.	5.0	95
33	An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults. Journal of Infectious Diseases, 2017, 216, 1362-1370.	4.0	88
34	Experimental infection of humans with A2 respiratory syncytial virus1. Antiviral Research, 2004, 63, 191-196.	4.1	86
35	Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines— Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum—Given Concomitantly with Influenza Vaccine to Highâ€Risk Elderly Individuals. Journal of Infectious Diseases, 2008, 198, 1317-1326.	4.0	83
36	The "Common Cold―in Frail Older Persons: Impact of Rhinovirus and Coronavirus in a Senior Daycare Center. Journal of the American Geriatrics Society, 1997, 45, 706-711.	2.6	82

#	Article	IF	CITATIONS
37	The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2020, 222, S563-S569.	4.0	74
38	Risk Factors for Respiratory Failure Associated with Respiratory Syncytial Virus Infection in Adults. Journal of Infectious Diseases, 2009, 200, 1242-1246.	4.0	73
39	Evaluation of a Handwashing Intervention to Reduce Respiratory Illness Rates in Senior Day-Care Centers. Infection Control and Hospital Epidemiology, 1999, 20, 200-202.	1.8	70
40	Neonatal gut and respiratory microbiota: coordinated development through time and space. Microbiome, 2018, 6, 193.	11.1	68
41	Evaluation of Four Methods for the Diagnosis of Respiratory Syncytial Virus Infection in Older Adults. Journal of the American Geriatrics Society, 1996, 44, 71-73.	2.6	64
42	Detection of Respiratory Viruses in Sputum from Adults by Use of Automated Multiplex PCR. Journal of Clinical Microbiology, 2014, 52, 3590-3596.	3.9	64
43	Novel coronavirus and severe acute respiratory syndrome. Lancet, The, 2003, 361, 1312-1313.	13.7	61
44	Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017–2020. Clinical Infectious Diseases, 2022, 74, 1004-1011.	5.8	61
45	Hepatitis B immunization of healthy elderly adults: relationship between naÃ⁻ve CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. Journal of Clinical Immunology, 2001, 21, 30-36.	3.8	59
46	Yield of Sputum for Viral Detection by Reverse Transcriptase PCR in Adults Hospitalized with Respiratory Illness. Journal of Clinical Microbiology, 2012, 50, 21-24.	3.9	57
47	Human Metapneumovirus Infection in Adults. Pediatric Infectious Disease Journal, 2008, 27, S80-S83.	2.0	55
48	Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. European Respiratory Journal, 2021, 57, 2002688.	6.7	55
49	Transcriptomic Biomarkers to Discriminate Bacterial from Nonbacterial Infection in Adults Hospitalized with Respiratory Illness. Scientific Reports, 2017, 7, 6548.	3.3	54
50	Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2020, 222, S570-S576.	4.0	54
51	Longâ€Term Care Facilities: A Cornucopia of Viral Pathogens. Journal of the American Geriatrics Society, 2008, 56, 1281-1285.	2.6	53
52	Should clinical case definitions of influenza in hospitalized older adults include fever?. Influenza and Other Respiratory Viruses, 2015, 9, 23-29.	3.4	53
53	Reverse transcription polymerase chain reaction (RT-PCR) for diagnosis of respiratory syncytial virus infection in adults: Use of a single-tube ?hanging droplet? nested PCR. Journal of Medical Virology, 2001, 63, 259-263.	5.0	50
54	Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. Vaccine, 2016, 34, 4843-4849.	3.8	49

#	Article	IF	CITATIONS
55	Risk Factors for Respiratory Syncytial Virus Illness Among Patients with Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 293-299.	1.6	48
56	Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. , 1999, 59, 221-226.		45
57	The Effect of Steroid Use in Hospitalized Adults With Respiratory Syncytial Virus-Related Illness. Chest, 2011, 140, 1155-1161.	0.8	45
58	Humoral immunity to respiratory syncytial virus infection in the elderly. Journal of Medical Virology, 1992, 36, 39-43.	5.0	44
59	Respiratory syncytial virus–associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure. Journal of Medical Virology, 2019, 91, 65-71.	5.0	43
60	Host Gene Expression in Nose and Blood for the Diagnosis of Viral Respiratory Infection. Journal of Infectious Diseases, 2019, 219, 1151-1161.	4.0	43
61	Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2022, 9, .	0.9	43
62	Respiratory Syncytial Virus Infection in Adults. Antiviral Therapy, 2007, 12, 659-670.	1.0	40
63	Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. International Journal of COPD, 2012, 7, 127.	2.3	39
64	Humoral immunity to human metapneumovirus infection in adults. Vaccine, 2010, 28, 1477-1480.	3.8	36
65	Current management of parainfluenza pneumonitis in immunocompromised patients: a review. Infection and Drug Resistance, 2012, 5, 121.	2.7	35
66	Consequences of Immature and Senescent Immune Responses for Infection with Respiratory Syncytial Virus. Current Topics in Microbiology and Immunology, 2013, 372, 211-231.	1.1	35
67	Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2018, 218, 208-217.	4.0	34
68	Disease Burden Estimates of Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With Comorbidity: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2022, 226, S17-S21.	4.0	34
69	Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. Vaccine, 2015, 33, 1151-1159.	3.8	32
70	Development of a Global Respiratory Severity Score (GRSS) for Respiratory Syncytial Virus Infection in Infants. Journal of Infectious Diseases, 2017, 215, jiw624.	4.0	32
71	The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies. Vaccine, 2020, 38, 6485-6486.	3.8	31
72	Microbiome-Transcriptome Interactions Related to Severity of Respiratory Syncytial Virus Infection. Scientific Reports, 2019, 9, 13824.	3.3	30

#	Article	IF	CITATIONS
73	Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses. Frontiers in Immunology, 2015, 6, 431.	4.8	27
74	The Healthy Infant Nasal Transcriptome: A Benchmark Study. Scientific Reports, 2016, 6, 33994.	3.3	25
75	Syncope, Near Syncope, or Nonmechanical Falls as a Presenting Feature of COVID-19. Annals of Emergency Medicine, 2020, 76, 115-117.	0.6	22
76	Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017–2019. Influenza and Other Respiratory Viruses, 2022, 16, 151-158.	3.4	22
77	Diversifying Selection Analysis Predicts Antigenic Evolution of 2009 Pandemic H1N1 Influenza A Virus in Humans. Journal of Virology, 2015, 89, 5427-5440.	3.4	21
78	Effect of prior vaccination on carriage rates of Streptococcus pneumoniae in older adults: A longitudinal surveillance study. Vaccine, 2018, 36, 4304-4310.	3.8	21
79	Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial. PLoS ONE, 2016, 11, e0152986.	2.5	19
80	Can Analysis of Routine Viral Testing Provide Accurate Estimates of Respiratory Syncytial Virus Disease Burden in Adults?. Journal of Infectious Diseases, 2017, 215, 1706-1710.	4.0	19
81	Detection of genetic lineages of human metapneumovirus in Croatia during the winter season 2005/2006. Journal of Medical Virology, 2008, 80, 1282-1287.	5.0	17
82	Association of Dynamic Changes in the CD4 T-Cell Transcriptome With Disease Severity During Primary Respiratory Syncytial Virus Infection in Young Infants. Journal of Infectious Diseases, 2017, 216, 1027-1037.	4.0	17
83	Airway Gene Expression Correlates of Respiratory Syncytial Virus Disease Severity and Microbiome Composition in Infants. Journal of Infectious Diseases, 2021, 223, 1639-1649.	4.0	17
84	Viral pathogens associated with acute respiratory illness in hospitalized adults and elderly from Zagreb, Croatia, 2016 to 2018. Journal of Medical Virology, 2019, 91, 1202-1209.	5.0	16
85	Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and postâ€discharge assessed by Respiratory Intensity and Impact Questionnaire. Influenza and Other Respiratory Viruses, 2022, 16, 79-89.	3.4	16
86	Microneutralization assay for the measurement of neutralizing antibodies to human metapneumovirus. Journal of Clinical Virology, 2009, 46, 314-317.	3.1	15
87	Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus. PLoS ONE, 2016, 11, e0153019.	2.5	14
88	Management of Respiratory Infections with Use of Procalcitonin: Moving toward More Personalized Antibiotic Treatment Decisions. ACS Infectious Diseases, 2017, 3, 875-879.	3.8	13
89	New emerging technologies and the intradermal route: the novel way to immunize against influenza. Vaccine, 2010, 28, D24-D32.	3.8	11
90	Temporal Dysbiosis of Infant Nasal Microbiota Relative to Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2021, 223, 1650-1658.	4.0	9

#	Article	lF	CITATIONS
91	Aims, Study Design, and Enrollment Results From the Assessing Predictors of Infant Respiratory Syncytial Virus Effects and Severity Study. JMIR Research Protocols, 2019, 8, e12907.	1.0	9
92	Viral Diagnostics: Only Half the Battle. Journal of Infectious Diseases, 2017, 216, 923-925.	4.0	8
93	The effect of air pollution on the transcriptomics of the immune response to respiratory infection. Scientific Reports, 2021, 11, 19436.	3.3	7
94	Serum levels of anti-PF4 lgG after AZD1222 (ChAdOx1 nCoV-19) vaccination. Scientific Reports, 2022, 12, 7961.	3.3	7
95	Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and <i>post-hoc</i> correlate of protection analysis. Human Vaccines and Immunotherapeutics, 2016, 12, 3043-3055.	3.3	5
96	Influenza burden in frail elderly. Lancet Respiratory Medicine,the, 2018, 6, e2.	10.7	5
97	What is the role of rapid molecular testing for seniors and other at-risk adults with respiratory syncytial virus infections?. Journal of Clinical Virology, 2019, 117, 27-32.	3.1	5
98	2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate. Open Forum Infectious Diseases, 2019, 6, S970-S970.	0.9	5
99	Airway gene-expression classifiers for respiratory syncytial virus (RSV) disease severity in infants. BMC Medical Genomics, 2021, 14, 57.	1.5	5
100	Aberrant newborn TÂcell and microbiota developmental trajectories predict respiratory compromise during infancy. IScience, 2022, 25, 104007.	4.1	5
101	733. Incidence and Evaluation of the Change in Functional Status Associated with Respiratory Syncytial Virus Infection in Hospitalized Older Adults. Open Forum Infectious Diseases, 2018, 5, S263-S263.	0.9	3
102	Measuring the Severity of Respiratory Illness in the First 2ÂYears of Life in Preterm and Term Infants. Journal of Pediatrics, 2019, 214, 12-19.e3.	1.8	3
103	Highly efficient hypothesis testing methods for regression-type tests with correlated observations and heterogeneous variance structure. BMC Bioinformatics, 2019, 20, 185.	2.6	3
104	Respiratory Syncytial Virus: An Old Foe in a New Era. Journal of Infectious Diseases, 2020, 222, 1245-1246.	4.0	3
105	Diagnosis of Streptococcus pneumoniae infection using circulating antibody secreting cells. PLoS ONE, 2021, 16, e0259644.	2.5	3
106	A systems genomics approach uncovers molecular associates of RSV severity. PLoS Computational Biology, 2021, 17, e1009617.	3.2	3
107	Pseudomonas Endocarditis with an unstable phenotype: the challenges of isolate characterization and Carbapenem stewardship with a partial review of the literature. Antimicrobial Resistance and Infection Control, 2017, 6, 87.	4.1	2
108	92. Incidence of Respiratory Syncytial Virus Infection among Hospitalized Adults, 2017–2019. Open Forum Infectious Diseases, 2019, 6, S7-S8.	0.9	1

#	Article	IF	CITATIONS
109	796. Burden of Healthcare-associated (HA) Respiratory Syncytial Virus (RSV) in Hospitalized Adults. Open Forum Infectious Diseases, 2021, 8, S494-S494.	0.9	1
110	Reply to Musher et al. Journal of Infectious Diseases, 2014, 209, 633-635.	4.0	0
111	Compassionate Use Experience with High Titer RSV Immunoglobulin (RSV-IVIG) in RSV Infected Immunocompromised Persons. Open Forum Infectious Diseases, 2016, 3, .	0.9	Ο
112	LytA-Positive Streptococcus mitis/oralis Confound Interpretation of Pneumococcal Colonization Studies. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
113	2315. The Relationship of Pre-Hospital Functional Status and Clinical Outcomes in Patients with Laboratory-Confirmed RSV Infection: Active Population-Based Surveillance, 2017–2019. Open Forum Infectious Diseases, 2019, 6, S794-S794.	0.9	0
114	415. Airway Gene-Expression Classifiers for Respiratory Syncytial Virus (RSV) Disease Severity in Infants. Open Forum Infectious Diseases, 2019, 6, S210-S210.	0.9	0
115	Unbiased analysis of peripheral blood mononuclear cells reveals CD4 T cell response to RSV matrix protein. Vaccine: X, 2020, 5, 100065.	2.1	0
116	Perceived Everyday Discrimination and C- Reactive Protein Influence on Cognition of Older Black Adults. Innovation in Aging, 2021, 5, 1040-1040.	0.1	0
117	Safety and Tolerability of an Ad26.RSV.preF-based Vaccine in a Phase 2b Study in Older Adults. Innovation in Aging, 2021, 5, 1045-1045.	0.1	0